Gene therapy: Role in myocardial protection

2Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Heart failure associated with coronary artery disease is amajor cause of morbidity and mortality. Recent developments in the understanding of the molecular mechanisms of heart failure have led to the identification of novel therapeutic targets which, combined with the availability of efficient gene delivery vectors, offer the opportunity for the design of gene therapies for protection of themyocardium. Viral-based therapies have been developed to treat polygenic and complex diseases such as myocardial ischaemia, hypertension, atherosclerosis and restenosis. Some of these experimental therapies are now undergoing clinical evaluation in patients with cardiovascular diseases. In this review we will focus on the latest advances in the field of gene therapy for treatment of heart failure and their clinical application. © 2006 Springer-Verlag Berlin Heidelberg.

Cite

CITATION STYLE

APA

Pachori, A. S., Melo, L. G., & Dzau, V. J. (2006). Gene therapy: Role in myocardial protection. Handbook of Experimental Pharmacology, 176(PART2), 335–350. https://doi.org/10.1007/3-540-36028-x_11

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free